IVIg therapy has potentially been related to arterial and venous therapy. We performed an Ovid review focusing on IVIg and thrombotic events. While a few case reports were reviewed case series and case control studies were particularly reviewed in relation to thrombotic events. Outcomes demonstrate a correlation between underlying cardiovascular risk factors with predominately arterial events which typically occurred within 4-24 hours of infusion. While venous events occurred less commonly they were associated with traditional risk factors and occurred later, typically, 1-7 days following infusion of IVIg. Potential causation of thrombotic events was discussed.